The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time. Photo omniscience.bio

Houston data science firm OmniScience announced this month that it has partnered with Florida-based INmune Bio (NASDAQ: INMB) on a global Phase 2 Alzheimer’s disease clinical trial.

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time, according to a release. The two companies also partnered during Vivo’s development and recent roll-out.

"OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” Angela Holmes, CEO of OmniScience, says in a statement. “As our partnership moves forward, we’re gaining further insights from the INmune team that we can integrate into Vivo’s roadmap. We look forward to our continued mutual success.”

The ADO2 trial will investigate INmune Bio's clinical-stage biotechnology XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation, according to its website. Its products are focused on "restoring function in the body's innate immune system to fight disease."

The trial is overenrolled with 208 patients diagnosed with mild Alzheimer’s disease or mild cognitive impairment. The top-line results are expected to be released in Q2 2025.

"A global trial of this size is vast, and Vivo will be critical in our ability to analyze cognitive results,” Tara Lehner, INmune Bio’s vice president of clinical operations, says in the statement. “With genAI provided by Vivo, we can amplify our clinical teams’ capabilities, turning complex data into actionable insights at unprecedented speed, which means we can get answers—and treatments—to patients faster.”

INmune will be able to use OmniScience's Vivo product to unify data from electronic data capture, clinical trial management systems, patient-reported outcomes, clinical outcome assessments, labs, wearables, safety databases and more, according to the statement. The product has been shown to improve data quality and visualizations and reduce the reliance on spreadsheet-based data analysis during clinical trials.

Omniscience was originally founded in 2017, then known as Mercury Data Science. It rebranded and changed its name earlier this year. Holmes was named CEO in 2022.

Omniscience's Vivo product recently won first place in the CNS Summit 2024 Innovation Showcase in Boston and the Blue Whale Ribbon at the inaugural Whale Tank pitch competition during the 2024 Innovation Network Gathering (ING) in West Chester, Pennsylvania.

MD Anderson’s goal with the new Institute for Data Science in Oncology is to advance collaborative projects that will bring the power of data science to every decision made at the hospital. Photo via mdanderson.org

Houston organization introduces inaugural cancer-fighting cohort of data sciences, experts

new to hou

The University of Texas MD Anderson Cancer Center is one step closer to ending cancer thanks to its new institute that's focused on data science.

MD Anderson’s goal with the new Institute for Data Science in Oncology (IDSO) is to advance collaborative projects that will bring the power of data science to every decision made at the hospital. And now, the IDSO has announced its inaugural cohort of 33 scientists, clinicians, and staff that will bring it to life, joining the already appointed leadership and focus area co-leads.

“By engaging diverse expertise across all of our mission areas, we will enhance the rich and productive data science ecosystem at MD Anderson to deliver transformational impact for patients,” David Jaffray, Ph.D., director of IDSO and chief technology and digital officer at MD Anderson, says in a press release.

The focus areas for the IDSO are quantitative pathology and medical imaging; single-cell analytics; computational modeling for precision medicine; decision analytics for health; and safety, quality, and access.

The IDSO Affiliates, as they are known, are a mix of existing contributors to the IDSO and team members who were recruited specifically for their expertise in data science. The affiliates were chosen to fulfill a two-year term, during which they will focus on IDSO projects related to the focus areas above. The diverse roster of professionals includes:

“Our affiliates bring expertise, perspectives and commitment from across the institution to foster impactful data science in order to tackle the most urgent needs of our patients and their families,” said Caroline Chung, M.D., director of Data Science Development and Implementation for IDSO and chief data officer at MD Anderson. “People and community are at the heart of our efforts, and establishing the IDSO Affiliates is an exciting step in growing the most impactful ecosystem for data science in the world.”

Aziz Gilani, managing director at Mercury, joins the Houston Innovators Podcast. Photo via LinkedIn

Houston investor on SaaS investing and cracking product-market fit

Houston innovators podcast episode 230

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption."



An example of this type of company is Houston-based RepeatMD, which raised a $50 million series A round last November. Mercury's Fund V, which closed at an oversubscribed $160 million, contributed to RepeatMD's round.

"While looking at that investment, it really made me re-calibrate a lot of my thoughts in terms what product-market fit meant," Gilani says. "At RepeatMD, we had customers that were so eager for the service that they were literally buying into products while we were still making them."

Gilani says he's focused on finding more of these high-growth companies to add to Mercury's portfolio amidst what, admittedly, has been a tough time for venture capital. But 2024 has been looking better for those fundraising.

"We've some potential for improvement," Gilani says. "But overall, the environment is constrained, interest rates haven't budged, and we've seen some potential for IPO activity."

Gilani shares more insight into his investment thesis, what areas of tech he's been focused on recently, and how Houston has developed as an ecosystem on the podcast.

Blue People has named Luis Arregoces as the company’s first chief artificial intelligence officer. Photo courtesy of Blue People

Houston software shop bets on AI with new C-suite member

eyes on AI

A Houston-based software company has named its first chief artificial intelligence officer.

Blue People has named Luis Arregoces as the company’s CAIO. With 20 years of experience, Arregoces has led AI projects for global Fortune 100 companies in various industries.

He has a Ph.D. in Economics from the University of New Mexico and is an adjunct professor in Statistics and Data Science at the University of Houston. He previously led the Applied Intelligence and Data Science at Accenture's Innovation Hub.

“We are beyond excited to have Luis on board,” Alfredo Arvide, chief innovation officer of Blue People, says in a news release. “His leadership and vision will allow Blue People to help clients and C-level executives develop AI roadmaps and solutions for real-time analytics, secure data sharing, and technology-agnostic ecosystems that will shape the future of innovation across all industries in Houston and throughout the region.”

Blue People has offices in Houston, Austin, Texas, and Monterrey, México. Blue People was named People’s Choice: Startup of the Year at the 2023 Houston Innovation Awards. The company also recently participated in CodeLaunch Houston, where its startup partner won the judges' pick in the competition.

“I am honored to join Blue People and be a part of this historic moment,” Arregoces says in a news release. ”Together, we have the opportunity to shape the future of AI in Houston and beyond. AI’s versatility and transformative potential make it indispensable across all industries to drive innovations, efficiency, and competitiveness.”

A Rice University student decided to use his data science skills for good. Photo courtesy of Biokind Analytics

Houston student launches data science nonprofit to support the health care industry

analytics for good

For Alex Han, it all started with peanut butter.

Han was a high school student in Korea when he learned that the spread is a pure odorant that could be used to test smell in each hemisphere of the brain—issues on the left side was thought to be a predictor for Alzheimer’s disease. He later learned that the method wasn’t as airtight as previously thought, but Han was hooked. Alzheimer’s research became the teenager’s passion. While still in high school, Han began volunteering for Alzheimer’s Los Angeles, translating their brochures into Korean.

When it came time to choose a college, Han says Rice University appealed to him for many reasons.

“I loved the atmosphere. I loved the campus—it’s so beautiful. The diverse food, the people, I even liked the highway,” he says of Houston. “In Korea, everything is so close and compact. I loved the whole scenario of the city.”

A scholarship was also part of the appeal, as well as the pull of the world’s largest medical center. Han’s instincts were correct. Now, a junior at Rice, he has been working at renowned geneticist Huda Zoghbi’s Baylor College of Medicine lab for almost two years.

But dividing his obligations between full-time studies and his wet lab position wasn’t enough to keep Han’s active mind occupied. Last May, the statistics and biochemistry student began another endeavor that uses both his specialties. It was then that he founded Biokind Analytics. The nonprofit was designed to explore how data science can support health care nonprofits.

Han reached out to Alzheimer’s Los Angeles to offer his data analysis services on a volunteer basis and was shocked that the association had never considered it before.

“I was really surprised—even small stores and restaurants use statistics to boost their profits. [Alzheimer’s Los Angeles] receive a couple million dollars every year in donations. They have data stores but hadn’t really capitalized yet in the area of analytics.”

Han, along with a small team of Rice students, including vice president Zac Andrews and development director Masha Zaitsev, made Alzheimer’s Los Angeles a pet project, analyzing geospatial trends in its donorship and interpreting the past year’s donation trends. “We wanted to see if the demand was the same in Houston. We found that this pattern was consistent. A lot of nonprofits are willing to have us analyze the data sets they’ve already been tracking and provide data analysis for healthcare nonprofits.”

Less than a year after Han established Biokind Analytics, the 501(c)(3) already has seven chapters on college campuses around the country. From UC Davis and San Diego in the West to Brown University and the University of Virginia on the East Coast, the data science students have helped a diverse range of medical nonprofits, mostly based in the Houston area. They run the gamut from ALS Association of Texas to Nora’s Home, which serves organ failure and transplant patients.

Biokind Analytics has now completed seven projects and analyzed $100 million in funds. Each student group includes four to six members, mostly majors in the worlds of statistics, data science, and biochemistry, all working with the help of faculty advisors. At a total of about 35 students nationwide, Han says that he’s dedicated to growing at a steady pace to avoid potentially expanding too fast, too soon.

Another question for the future is what will happen to Biokind Analytics when Han completes his undergraduate studies in 2024. He plans to continue his medical studies with the goal of one day becoming a physician specializing in Alzheimer’s who uses data analytics to aid in patient care. But no matter how active Han continues to be in the nonprofit he started, his stated attachment to the cause and a growing group of both student leaders and healthcare associations eager for their services are sure to keep Biokind Analytics active long after graduation.

Let's talk about dark data — what it means and how to navigate it. Graphic by Miguel Tovar/University of Houston

Houston expert: Navigating dark data within research and innovation

houston voices

Is it necessary to share ALL your data? Is transparency a good thing or does it make researchers “vulnerable,” as author Nathan Schneider suggests in the Chronicle of Higher Education article, “Why Researchers Shouldn’t Share All Their Data.”

Dark Data Defined

Dark data is defined as the universe of information an organization collects, processes and stores – oftentimes for compliance reasons. Dark data never makes it to the official publication part of the project. According to the Gartner Glossary, “storing and securing data typically incurs more expense (and sometimes greater risk) than value.”

This topic is reminiscent of the file drawer effect, a phenomenon which reflects the influence of the results of a study on whether or not the study is published. Negative results can be just as important as hypotheses that are proven.

Publication bias and the need to only publish positive research that supports the PI’s hypothesis, it can be argued, is not good science. According to an article in the Indian Journal of Anaesthesia, authors Priscilla Joys Nagarajan, et al., wrote: “It is speculated that every significant result in the published world has 19 non-significant counterparts in file drawers.” That’s one definition of dark data.

Total Transparency

But what to do with all your excess information that did not make it to publication, most likely because of various constraints? Should everything, meaning every little tidbit, be readily available to the research community?

Schneider doesn’t think it should be. In his article, he writes that he hides some findings in a paper notebook or behind a password, and he keeps interviews and transcripts offline altogether to protect his sources.

Open-source

Open-source software communities tend to regard total transparency as inherently good. What are the advantages of total transparency? You may make connections between projects that you wouldn’t have otherwise. You can easily reproduce a peer’s experiment. You can even become more meticulous in your note-taking and experimental methods since you know it’s not private information. Similarly, journalists will recognize this thought pattern as the recent, popular call to engage in “open journalism.” Essentially, an author’s entire writing and editing process can be recorded, step by step.

TMI

This trend has led researchers to open-source programs like Jupyter and GitHub. Open-source programs detail every change that occurs along a project’s timeline. Is unorganized, excessive amounts of unpublishable data really what transparency means? Or does it confuse those looking for meaningful research that is meticulously curated?

The Big Idea

And what about the “vulnerability” claim? Sharing every edit and every new direction taken opens a scientist up to scoffers and harassment, even. Dark data in industry even involves publishing salaries, which can feel unfair to underrepresented, marginalized populations.

In Model View Culture, Ellen Marie Dash wrote: “Let’s give safety and consent the absolute highest priority, with openness and transparency prioritized explicitly below those. This means digging deep, properly articulating in detail what problems you are trying to solve with openness and transparency, and handling them individually or in smaller groups.”

------

This article originally appeared on the University of Houston's The Big Idea. Sarah Hill, the author of this piece, is the communications manager for the UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston space company lands latest NASA deal to advance lunar logistics

To The Moon

Houston-based space exploration, infrastructure, and services company Intuitive Machines has secured about $2.5 million from NASA to study challenges related to carrying cargo on the company’s lunar lander and hauling cargo on the moon. The lander will be used for NASA’s Artemis missions to the moon and eventually to Mars.

“Intuitive Machines has been methodically working on executing lunar delivery, data transmission, and infrastructure service missions, making us uniquely positioned to provide strategies and concepts that may shape lunar logistics and mobility solutions for the Artemis generation,” Intuitive Machines CEO Steve Altemus says in a news release.

“We look forward to bringing our proven expertise together to deliver innovative solutions that establish capabilities on the [moon] and place deeper exploration within reach.”

Intuitive Machines will soon launch its lunar lander on a SpaceX Falcon 9 rocket to deliver NASA technology and science projects, along with commercial payloads, to the moon’s Mons Mouton plateau. Lift-off will happen at NASA’s Kennedy Space Center in Florida within a launch window that starts in late February. It’ll be the lander’s second trip to the moon.

In September, Intuitive Machines landed a deal with NASA that could be worth more than $4.8 billion.

Under the contract, Intuitive Machines will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. The initial round of NASA funding runs through September 2029.

Play it back: Houston home tech startup begins 2025 with fresh funding

HOUSTON INNOVATORS PODCAST EPISODE 272

One of the dozen or so Houston startups kicking of the new year with fresh funding is SmartAC.com, a company that's designed a platform that enables contractors in the HVAC and plumbing industries to monitor, manage, and optimize their maintenance memberships through advanced sensors, AI-driven diagnostics, and proactive alerts.

Last month, the SmartAC.com raised a follow-on round with support from local investor Mercury to continue growth and expansion of the product, which has evolved on many ways since the company launched in 2020, emerging from stealth with $10 million raised in a series A. In a May 2023 interview for the Houston Innovators Podcast, Founder and CEO Josh Teekell explained how he embraced the power of a pivot.

The company's sensors can monitor all aspects of air conditioning units and report back any issues, meaning homeowners have quicker and less costly repairs. While SmartAC.com started with providing the service and tech to homeowners directly, Teekell says he's had a greater interest in working with plumbers and HVAC companies who then deploy the technology to their customers.

"It became quite evident that homeowners don't care about air conditioning really at all until their system breaks," Teekell says on the show. "The technology is really built around giving those contractors as another way to gain a customer relationship and keep it."

Revisit the podcast episode below where Teekell talks about SmartAC.com's last raise.

SmartAC.com's previous round in 2023 — a $22 million series B — was used grow its team that goes out to deploy the technology and train the contractors on the platform.

"We've been very fortunate to get some of the biggest names in Houston on our cap table," Teekell says in the May 2023 conversation. "Since we're raising a bunch of money locally, everyone understands what a pain air conditioning can be."

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.